MY184103A - Novel cho integration sites and uses thereof - Google Patents

Novel cho integration sites and uses thereof

Info

Publication number
MY184103A
MY184103A MYPI2017701254A MYPI2017701254A MY184103A MY 184103 A MY184103 A MY 184103A MY PI2017701254 A MYPI2017701254 A MY PI2017701254A MY PI2017701254 A MYPI2017701254 A MY PI2017701254A MY 184103 A MY184103 A MY 184103A
Authority
MY
Malaysia
Prior art keywords
expression
integration sites
enhanced
eukaryotic
novel cho
Prior art date
Application number
MYPI2017701254A
Other languages
English (en)
Inventor
Ying Shen
Darya Burakov
Gang Chen
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54602002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY184103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY184103A publication Critical patent/MY184103A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
MYPI2017701254A 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof MY184103A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (1)

Publication Number Publication Date
MY184103A true MY184103A (en) 2021-03-18

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017701254A MY184103A (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Country Status (16)

Country Link
US (5) US9816110B2 (enExample)
EP (1) EP3209785B1 (enExample)
JP (1) JP6668340B2 (enExample)
KR (1) KR102243243B1 (enExample)
CN (1) CN107109434B (enExample)
AR (1) AR102420A1 (enExample)
AU (1) AU2015335921B2 (enExample)
BR (1) BR112017008022A2 (enExample)
CA (1) CA2965495C (enExample)
EA (1) EA037255B1 (enExample)
IL (1) IL251674B (enExample)
MX (1) MX2017005306A (enExample)
MY (1) MY184103A (enExample)
SG (1) SG11201703149RA (enExample)
TW (2) TWI747808B (enExample)
WO (1) WO2016064999A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
US11530277B2 (en) * 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP2020501593A (ja) * 2016-12-20 2020-01-23 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology 改変細胞、調製方法、及び構築物
WO2018148196A1 (en) * 2017-02-07 2018-08-16 Sigma-Aldrich Co. Llc Stable targeted integration
WO2018150271A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
US11959093B2 (en) 2017-03-19 2024-04-16 Applied Stemcell, Inc. Integration sites and uses thereof
KR102531749B1 (ko) * 2017-08-11 2023-05-10 베링거 인겔하임 인터내셔날 게엠베하 Cho 세포 내 통합 부위
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
WO2019126562A1 (en) * 2017-12-22 2019-06-27 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
EP3980544A1 (en) * 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Targeted integration of nucleic acids
SG11202110076PA (en) * 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP3990649A1 (en) 2019-06-26 2022-05-04 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
JP7887833B2 (ja) * 2020-06-02 2026-07-10 キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー 遺伝子挿入用の複数のドックを有している細胞株
KR20230027043A (ko) * 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
WO2022079083A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
CN118159660A (zh) 2021-10-18 2024-06-07 瑞泽恩制药公司 多核苷酸的受控转录
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
US20250098652A1 (en) * 2022-01-28 2025-03-27 The Trustees Of Columbia University In The City Of New York Genetic Modifications for Xenotransplantation
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
US20240168018A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and evaluating viruses and virus-like particles
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production
WO2026162509A1 (en) 2025-01-28 2026-08-06 Selexis Sa Integration regions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ES2375266T3 (es) 1998-07-21 2012-02-28 Millipore Corporation Un polinucleótido que comprende un elemento de apertura de cromatina ubicuo (ucoe).
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU2002254529A1 (en) 2001-04-04 2002-10-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
DK2150617T3 (en) * 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
EP3156494B8 (en) * 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
CA2832095A1 (en) 2011-04-05 2012-10-11 The Scripps Research Institute Chromosomal landing pads and related uses
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP3683319A1 (en) * 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
US9222105B2 (en) * 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof

Also Published As

Publication number Publication date
JP2017535258A (ja) 2017-11-30
CN107109434B (zh) 2026-05-26
CA2965495A1 (en) 2016-04-28
EA201790698A1 (ru) 2018-01-31
TW202144576A (zh) 2021-12-01
BR112017008022A2 (pt) 2018-02-20
IL251674A0 (en) 2017-06-29
EP3209785A1 (en) 2017-08-30
JP6668340B2 (ja) 2020-03-18
MX2017005306A (es) 2018-01-09
SG11201703149RA (en) 2018-02-27
US20180030480A1 (en) 2018-02-01
US12565667B2 (en) 2026-03-03
WO2016064999A1 (en) 2016-04-28
EP3209785B1 (en) 2019-07-31
AR102420A1 (es) 2017-03-01
US20210171984A1 (en) 2021-06-10
TWI747808B (zh) 2021-12-01
KR102243243B1 (ko) 2021-04-22
KR20170096999A (ko) 2017-08-25
IL251674B (en) 2020-10-29
US11268109B2 (en) 2022-03-08
US20200002732A1 (en) 2020-01-02
US11788102B2 (en) 2023-10-17
US9816110B2 (en) 2017-11-14
US20240018553A1 (en) 2024-01-18
AU2015335921B2 (en) 2020-06-25
TWI780847B (zh) 2022-10-11
EA037255B1 (ru) 2021-02-26
CA2965495C (en) 2022-05-24
AU2015335921A1 (en) 2017-05-04
CN107109434A (zh) 2017-08-29
TW201629229A (zh) 2016-08-16
US20160115502A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
EA201790698A1 (ru) Новые сайты интеграции cho и их применения
CY1124627T1 (el) Στοχευμενη τροποποιηση γονιδιωματος αρουραιου
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
MX2025009055A (es) Vectores de neoantigeno de alfavirus
ZA202310779B (en) Compositions and methods for enhanced gene expression
MX2025014318A (es) Vector de adenovirus de chimpance util para la administracion de neoantigenos
PH12017502026A1 (en) Nuclease-mediated regulation of gene expression
EP4249074A3 (en) Genomic engineering of pluripotent cells
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
MX388127B (es) Metodos y composiciones para la modificacion dirigida de un genoma.
WO2017106537A3 (en) Targeted disruption of the mhc cell receptor
EP4089172A3 (en) Multiple vector system and uses thereof
WO2015157579A3 (en) Enhanced nucleic acid constructs for eukaryotic gene expression
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
NZ738689A (en) Engineered crispr-cas9 compositions and methods of use
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
EP4410978A3 (en) Methods for quantitative genetic analysis of cell free dna
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX353134B (es) Ratones con receptor de linfocitos t modificados geneticamente.
MX2017009506A (es) Polinucleotidos de acido desoxirribonucleico (adn)/acido ribonucleico (arn) hibridos de repeticiones palindromicas cortas agrupadas regularmente separadas (crispr) y sus metodos de uso.
MX2014012994A (es) Direccion transmitida por nucleasa con vectores de direccion grandes.
EP3237613A4 (en) Visualizing modified nucleotides and nucleic acid interactions in single cells
AU2017250265A1 (en) Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof
MX390143B (es) Secuencias recombinantes de cromosoma b de maíz y sus usos
WO2018144087A3 (en) Dna plasmids for the fast generation of homologous recombination vectors for cell line development